Mersana Therapeutics Inc (Mersana) is a clinical-stage biopharmaceutical company that develops novel antibody-drug conjugates (ADCs). The company develops drugs using Dolasynthen and Immunosynthen platforms. Its pipeline products include XMT-1660, a B7-H4-targeting multiple solid tumors; XMT-2056, a Novel HER2 Epitope that treats multiple solid tumors, XMT-2068 and XMT-2175. Mersana's products treat multiple cancer indications including breast, gastric, colorectal and non-small cell lung cancers. The company works in collaboration with Johnson & Johnson and Merck KGaA. Mersana is headquartered in Cambridge, Massachusetts, the US.
Mersana Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
XMT-1660: Multiple Solid Tumors |
XMT-2056: Multiple Solid Tumors |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Mersana Therapeutics Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc | Takeda Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United Kingdom | Japan |
City | Cambridge | New York | North Chicago | Cambridge | Chuo-Ku |
State/Province | Massachusetts | New York | Illinois | England | Tokyo |
No. of Employees | 123 | 88,000 | 50,000 | 89,900 | 49,095 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
David Mott | Chairman | Executive Board | 2012 | 58 |
Martin Huber, M.D. | Chief Executive Officer; President; Director | Executive Board | 2023 | 64 |
Brian DeSchuytner | Chief Financial Officer; Senior Vice President; Chief Operating Officer | Senior Management | 2023 | - |
Ashish Mandelia | Chief Accounting Officer; Vice President | Senior Management | 2023 | - |
Alejandra Carvajal | Chief Legal Officer; Senior Vice President | Senior Management | 2021 | 50 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer